Hostname: page-component-848d4c4894-tn8tq Total loading time: 0 Render date: 2024-06-26T10:56:50.615Z Has data issue: false hasContentIssue false
  • English
  • Français

Sudden hearing loss in a patient hepatitis C virus (HCV) positive on therapy with alpha-interferon: a possible autoimmune-microvascular pathogenesis

Published online by Cambridge University Press:  29 June 2007

G. Cadoni ,
L. Marinelli ,
A. De Santis ,
A. Romito ,
R. Manna  and
F. Ottaviani
G. Cadoni
Affiliation:
Institute of Otolaryngology, Catholic University of the Sacred Heart, Rome, Italy
L. Marinelli
Affiliation:
Institute of Otolaryngology, Catholic University of the Sacred Heart, Rome, Italy
A. De Santis
Affiliation:
Department of Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy
A. Romito
Affiliation:
Department of Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy
R. Manna
Affiliation:
Department of Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy
F. Ottaviani*
Affiliation:
Institute of Otolaryngology, Catholic University of the Sacred Heart, Rome, Italy
*
Address for correspondence: Prof. Fabrizio Ottaviani, Institute of Otolaryngology, Catholic University of the Sacred Heart, Largo Agostino Gemelli, 8, 00168 Rome, Italy Fax: +39 06 3051194
Get access Rights & Permissions [Opens in a new window]

Abstract

Alpha interferon (α-IFN) is used for the treatment of various systemic disorders. Side-effects of α-IFN therapy can involve numerous organ systems, but sudden hearing loss has only once been recorded. We report a case of sudden hearing loss occurring in a patient with chronic hepatitis C treated with α-IFN and recovered five days after the discontinuation of this agent. This is the first record of anti-endothelial cell antibodies detection in a patient with sudden hearing loss. The finding of anti-endothelial cell antibodies suggests an association between sudden hearing loss and microvascular damage during interferon therapy.

Keywords

Hearing loss, sensorineuralInterferon, alphaEndotheliumAntibody formation
Type
Clinical Records
Information
The Journal of Laryngology & Otology , Volume 112 , Issue 10 , October 1998 , pp. 962 - 963
Copyright
Copyright © JLO (1984) Limited 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alonso, K., Medenica, R. (1995) Immunomodulation in the treatment of multiple sclerosis and amyotrophic lateral sclerosis: a model for autoimmune disorders. Journal of National Medical Association 87: 561–568.Google Scholar
Brouty-Boye, D., Zetter, B. R. (1980) Inhibition of cell motility by interferon. Science 208: 516–518.CrossRefGoogle ScholarPubMed
Bykovskaia, G. N., Slepova, O. S., Krichevskaia, G. I., Katargina, L. A., Kushnir, V. N. (1997) Study of antibodies to DNA in patients with bilateral and unilateral endogenous uveitis. Vestnik Ophthalmology 113: 30–32.Google ScholarPubMed
Chakrabarti, D., Hultgren, B., Stewart, T. A. (1996) IFN-alpha induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B7.2. Journal of Immunology 157: 522–528.CrossRefGoogle ScholarPubMed
Chung, A., Older, S. A. (1997) Interferon-alpha associated arthritis. Journal of Rheumatology 24: 1844–1845.Google ScholarPubMed
Dusheiko, G. (1997) Side effects of alpha interferon in chronic hepatitis C. Hepatology 26 (Suppl): 112–121.CrossRefGoogle ScholarPubMed
Fabris, P., Betterle, C., Floreani, A., Greggio, N. A., de Lazzari, F., Naccarato, R., Chiaramonte, M. (1992) Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 340: 548.CrossRefGoogle ScholarPubMed
Guyer, D. R., Tiedman, J., Yannuzzi, L. A. (1993) Interferon-associated retinopathy. Archives of Ophthalmology 111: 350–356.CrossRefGoogle ScholarPubMed
Hadziyannis, S. J. (1997) The spectrum of extrahepatic manifestations in hepatitis C virus infection. Journal of Viral Hepatitis 4: 9–28.CrossRefGoogle ScholarPubMed
Kanda, Y., Shigeno, K., Kinoshita, N., Nakao, K., Yano, M., Matsuo, H. (1994) Sudden hearing loss associated with interferon. Lancet 343: 1134–1135.CrossRefGoogle ScholarPubMed
Kanda, Y., Shigeno, K., Matsuo, H., Yano, M., Yamada, N., Kumagami, H. (1995) Interferon-induced sudden hearing loss. Audiology 34: 98–102.CrossRefGoogle ScholarPubMed
Krown, S. E., Real, F. X., Cunningham-Rundles, S., Mys-kowski, P. L., Koziner, B., Fein, S., Mittelman, A., Oettgen, H. F., Safai, S. (1983) Preliminary observations of the effects of recombinant leukocyte and interferon in homosexual men with Kaposi's sarcoma. New England Journal of Medicine 308: 1071–1076.CrossRefGoogle ScholarPubMed
Lisker-Melman, M., Di Bisceglie, A. M., Usala, S. J., Weintraub, B., Murray, L. M., Hoofnagle, J. H. (1992) Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 102: 2155–2160.CrossRefGoogle ScholarPubMed
Lyons, J. L., Rosenbaum, J. T. (1997) Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. Archives of Ophthalmology 115: 61–64.CrossRefGoogle ScholarPubMed
Miossec, P.Cytokine-induced autoimmune disorders (1997) Drug Safety 17: 93–104.CrossRefGoogle ScholarPubMed
Quesada, J. R., Rios, A., Swanson, D., Trown, P., Gutterman, J. U. (1985) Anti-tumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. Journal of Clinical Oncology 3: 1522–1528.CrossRefGoogle Scholar
Sertoli, M. R., Bernengo, M. G., Ardizzoni, A., Brunetti, I., Falcone, A., Vidili, M. G., Cusimano, M. P., Appino, A., Doveil, G., Fortini, C. (1989) Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma. Oncology 46: 96–98.CrossRefGoogle ScholarPubMed
Skalla, K.The interferons (1996) Seminars in Oncology Nursing 12: 97–105.CrossRefGoogle ScholarPubMed
Soos, J. M., Johnson, H. M. (1995) Type I interferon inhibition of superantigen stimulation: implications for treatment of superantigen-associated disease. Journal of Interferon Cyto-kine Research 15: 39–45.CrossRefGoogle ScholarPubMed
Stiem, E. R. (1982) Interferon: immunobiology and clinical significance. Annals of International Medicine 96: 80–93.CrossRefGoogle Scholar
Tan, E. M., Pearson, C. M. (1972) Rheumatic disease sera reactive with capillaries in the mouse kidney. Arthritis and Rheumatology 15: 23–28.CrossRefGoogle ScholarPubMed
Tinghitella, T. J. (1990) Pathogenesis of viral infections: the role of the immune response. American Journal of Otolaryngology 11: 309–312.CrossRefGoogle ScholarPubMed
White, C. W., Sonheimer, H. M., Crouch, E. C., Wilson, H., Fan, L. L. (1989) Treatment of pulmonary hemangioma-tosis with recombinant interferon alfa-2a. New England Journal of Medicine 320: 1197–1200.CrossRefGoogle ScholarPubMed
Woo, M. H., Burnakis, T. G. (1997) Interferon alpha in the treatment of chronic viral hepatitis B and C. Annals of Pharmacotherapy 31: 330–337.CrossRefGoogle Scholar